Canada cancer biomarker market is growing at a CAGR of 11.4% during the forecast period. The healthcare industry of the Canada depends heavily on the demand created by the publicly funded and insured health care system of the country. The medical device industry consists of companies that produce a wide range of products which are used for the diagnosis and treatment of ailments. Canada is one of the potential markets for cancer biomarker. Canada has a population of 36 million in 2018 which accounts to 0.48% of the total world’s population. The geriatric population accounts for a considerable patient pool having cancers, in turn influencing the Canada cancer biomarkers market.
To learn more about this report request a free sample copy @ https://www.omrglobal.com/request-sample/canada-cancer-biomarker-market
According to the Canadian Cancer Statistics it was estimated that around 1 in 2 Canadian will have cancer in life time. On the other hand, 1 out of 4 will die due to cancer. According to the organization in the year 2017, more than 206,000 people were suffering from cancer. Additionally, more than 80,000 cases of deaths due to cancer were registered. The lung cancer is the leading cause of deaths in Canada.
Browse for Full Report Description@ https://www.omrglobal.com/industry-reports/canada-cancer-biomarker-market
Moreover, prostate cancer is one of the most prevalent cancer in Canadian men. It is the 3rd leading cause of mortality from cancer in men in Canada. Canadian Cancer Society estimated that around 21% of the new cancer cases in men will be diagnosed with prostate cancer that accounted for 21,300. It is estimated that 4100 mortalities will be recorded which will represent 10% of all mortalities from all cancers in 2017. On average 58 Canadian men will be diagnosed with prostate cancer every day and, 11 Canadian men will decrease from prostate cancer every day. Thus, the high prevalence creates scopes for the Canada cancer biomarker market during the forecast period.
Market Segmentation
Canada Cancer Biomarker Market by Biomarker Type
- Genetic Biomarker
- Protein Biomarker
Canada Cancer Biomarkers Market by Cancer Type
- Lung Cancer
- Prostate Cancer
- Breast Cancer
- Colorectal Cancer
- Cervical Cancer
- Other
Canada Cancer Biomarkers Market by Applications
- Drug Discovery and Development
- Diagnosis
- Risk Assessment
- Prognostics
Canada Cancer Biomarker Market by Profiling Technology
- Omics Technology
- Immunoassays
- Cytogenetics
- Bioinformatics
Company Profiles
- Abbott laboratories Inc.
- Astellas Pharma Inc.
- Becton, Dickson and Co.
- Bio-Rad Laboratories, Inc.
- Danaher Corp.
- Hoffmann-La Roche Ltd.
- Merck and Co., Inc.
- Novartis AG
- Pfizer Inc.
- QIAGEN GmbH
- Thermo Fisher Scientific Inc.
(This release has been published on OMR Industry Journal. OMR Industry Journal is not responsible for any content included in this release.)
